Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Standard-risk newly diagnosed B-ALL/B-lymphoblastic lymphoma maintenance methotrexate trial
2011-003430-13Phase 3Terminated
- Sponsor
- Children's Oncology Group
- Start
- Oct 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of methotrexate, mercaptopurine, vincristine, dexamethasone and folinic acid in B cell acute lymphoblastic leukemia (B-ALL) and B lymphoblastic lymphoma (B-LL) (5 arms), sponsored by Children's Oncology Group. Primary endpoint: 5-year disease-free survival improvement with methotrexate randomization. Started Oct 2013; status: terminated.
02
Drugs
methotrexatemercaptopurinevincristinedexamethasonefolinic acid
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B lymphoblastic lymphoma (B-LL)
Beyond the preview
Go deeper on 2011-003430-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003430-13.